The post SEC Charges Biotech Company and CEO With Fraud Concerning COVID-19 Blood Testing Device appeared first on Investor News.

Purdue Pharma LP pleaded responsible to prison costs over the dealing with of its addictive prescription painkiller OxyContin, capping a take care of federal prosecutors to resolve an investigation into the drugmaker’s function within the U.S. opioid disaster.

Throughout a courtroom listening to carried out remotely on Tuesday earlier than U.S. District Decide Madeline Cox Arleo in New Jersey, Purdue pleaded responsible to a few felonies masking widespread misconduct.

The prison violations included conspiring to defraud U.S. officers and pay unlawful kickbacks to each docs and an digital healthcare information vendor known as Observe Fusion right here, all to assist preserve opioid prescriptions flowing.

Members of the billionaire Sackler household who personal Purdue and beforehand sat on the corporate’s board weren’t a part of Tuesday’s courtroom proceedings and haven’t been criminally charged. They agreed in October to pay a separate $225 million civil penalty for allegedly inflicting false claims for OxyContin to be made to authorities healthcare packages resembling Medicare. They’ve denied the allegations.

Assistant U.S. Legal professional J. Stephen Ferketic mentioned officers reserved the fitting to prosecute people related to Purdue, together with house owners, officers and administrators. Sackler relations have mentioned they acted ethically and responsibly whereas serving on Purdue’s board and have been assured the corporate’s gross sales and advertising and marketing practices complied with authorized and regulatory necessities.

Purdue Chairman Steve Miller entered the responsible plea on the corporate’s behalf and admitted to its prison conduct underneath questioning from Ferketic. Of the three prison counts in opposition to Purdue, two have been for violations of a federal anti-kickback legislation whereas one other charged the Stamford, Connecticut-based firm with defrauding america and violating the Meals, Drug and Beauty Act.

Purdue’s plea deal carries greater than $5.5 billion in penalties, most of which is able to go unpaid.

A $3.54 billion prison superb is ready to be thought-about alongside trillions of {dollars} in unsecured claims as a part of Purdue’s chapter proceedings.

Purdue agreed to pay $225 million towards a $2 billion prison forfeiture, with the Justice Division foregoing the remainder if the corporate completes a chapter reorganization dissolving itself and shifting belongings to a “public profit firm” or comparable entity that steers the $1.775 billion unpaid portion to 1000’s of U.S. communities suing it over the opioid disaster.

A sentencing imposing these penalties is ready to return across the time Purdue receives courtroom approval for a chapter reorganization.

Purdue earlier settled separate Justice Division civil claims, agreeing to a $2.8 billion penalty additionally anticipated to obtain little monetary restoration within the drugmaker’s chapter case.

Perdue Function in Opioid Disaster

The plea deal and different associated settlements have come underneath fireplace from Democrats on Capitol Hill calling for Purdue and its house owners to face extra extreme penalties for his or her alleged roles within the opioid disaster.

The corporate reaped greater than $30 billion from gross sales of OxyContin over time, enriching Sackler relations, based on U.S. and state officers. Since 1999, roughly 450,000 folks have died in america from opioid-related overdoses, based on U.S. knowledge.

Some two dozen state attorneys common have oppose right here the plea deal on the grounds that it successfully endorses a chapter plan they contend would entangle native governments with a public profit firm that continues to promote OxyContin.

Purdue, which filed for chapter safety final yr right here underneath an onslaught of litigation, has proposed settling 1000’s of lawsuits in a deal it values at greater than $10 billion. That’s contingent on donations of opioid reversal and dependancy therapy drugs it has underneath improvement and a $3 billion money contribution from the Sacklers, who would cede management of Purdue.

Along with the kickbacks and vendor scheme, between 2007 and 2017, Purdue ignored docs suspected of improperly prescribing opioids that have been flagged by its inner controls, and did not report OxyContin prescriptions from these physicians to the Drug Enforcement Administration as legally required, based on prosecutors.

A Purdue affiliate in 2007 agreed to plead responsible to misbranding OxyContin in a take care of prosecutors that resulted in about $600 million of penalties.

The post Purdue Pharma Pleads Guilty to Three Felonies Over OxyContin Misconduct appeared first on Investor News.

US stocks have rocketed 28% this year. This is the second largest annual gain since 1999. And the tenth straight year stocks have climbed higher.

This has a lot of investors worried that stocks could tank soon. But this bull market is far from over. My research shows stocks should continue to rise until at least September 2020.

And falling interest rates could help that happen… especially for healthcare stocks.

Falling Rates Push Healthcare Stocks Higher

In July, the Federal Reserve cut interest rates for the first time in over a decade.

As a general rule, lower rates tend to push stocks higher—largely because it makes it cheaper for businesses to borrow and fuels spending.

Lower rates prop up healthcare stocks in particular. According to Barclays, they outperform the S&P 500 by an average of 7% in the nine months after an initial interest rate cut, like the one we saw in July.

That was almost five months ago. And the SPDR Health Care Sector ETF [ (XLV[ARCA] – $101.86 0.20 (0.20%)   )] has climbed 9% since. That’s nearly double the S&P 500’s 5.4% return, as the next chart shows.

Click to enlarge

I’ve covered three ways to play this trend back in July: Johnson & Johnson [ (JNJ[NYE] – $145.87 0.57 (0.39%)    Trade )], AbbVie Inc. [ (ABBV[NYE] – $88.54 0.02 (0.02%)    Trade )], and Abbott Laboratories [ (ABT[NYE] – $86.86 0.06 (0.07%)    Trade )]. Since then, these stocks have climbed an average of 10.1%:

Click to enlarge

That’s more than double the S&P 500’s return over the same period.

Impressive. But remember, if the pattern holds, we’re only halfway through this trend.

The Longview—We’re Getting Old

There are lots of reasons to like healthcare stocks.

To start, America is graying. The share of Americans age 65 and up will jump from 15% in 2018, and up to 21% by 2030.

This has straightforward implications: as people get older, they need more medical care. And it’s one of the last things people skimp on.

In fact, US healthcare spending will grow 5.5% annually through 2027, according to the Centers for Medicare and Medicaid Services (CMS).

Click to enlarge

Consistent spending means healthcare companies earn stable profits, pretty much no matter what.

This makes healthcare stocks ideal for income investors like us.

My New Top Healthcare Picks

Long-term increases in healthcare spending will push healthcare stock prices higher. Add in the short-term interest rate tailwind I mentioned earlier, and you’ve got good reason to hold healthcare stocks today.

The world’s largest medical device company, Medtronic plc [ (MDT[NYE] – $113.45 0.52 (0.46%)    Trade )], is at the top of my list. The company makes pacemakers, insulin pumps, and surgical tools.

The aging US population will keep these products in high demand for decades. This makes Medtronic’s stock and its 2.0% dividend yield very reliable.

Next on my list is global drug company GlaxoSmithKline PLC [ (GSK[NYE] – $46.99 0.09 (0.19%)    Trade )].

GlaxoSmithKline makes a variety of well-known medications, from the nasal spray Flonase, to the antidepressant Wellbutrin, to the antacid Zantac.

The company also holds key patents for highly profitable respiratory and antiviral therapies. This gives it very stable sales and profits.

Best of all, GlaxoSmithKline pays a reliable 4.2% dividend yield. That’s over twice the dividend yield on the S&P 500.

Finally, we have Merck & Co. Inc. [ (MRK[NYE] – $90.95 0.08 (0.09%)    Trade )], another major global drug company. Merck makes a broad range of products, from HIV therapies to insomnia medications and fertility drugs.

It’s also a leading maker of cancer treatments. We all know many cancers get more common with age. So the graying US population will keep Merck’s cancer therapies in high demand.

The company also pays a safe 2.7% dividend yield, which is great for income investors.

Again, I expect this bull market to keep chugging along into 2020. There’s plenty of upside left.

But you still want to control risk by holding safe and reliable dividend-paying stocks. Medtronic, GlaxoSmithKline and Merck fit the bill.

The post 3 Ways To Play the Healthcare Surge appeared first on Investor News.

7 simple steps to improving your chances of success in biotech investing

Exciting. Scary. Lucrative. Risky.

All of these adjectives apply to investing in biotech stocks. The excitement and the prospects for generating huge profits make biotech stocks appealing to many investors. On the other hand, the fear of big losses that stem from the high risk levels associated with many biotech stocks causes other investors to stay away.

How should you go about investing in biotech stocks? There are 7 key steps to follow that should improve your chances of success:

1. Know which stocks are biotech stocks — and which aren’t.
2. Determine your risk tolerance.
3. Understand the risks specific to biotech stocks.
4. Know what to look for in a biotech stock.
5. Evaluate the top biotech stocks and biotech exchange-traded funds (ETFs).
6. Invest cautiously.
7. Monitor changing dynamics.

Here’s what you need to know about each of these seven steps for investing in biotech stocks.

1. Know which stocks are biotech stocks — and which aren’t

First, you’ll want to know which stocks actually are biotechs and which aren’t. It’s not as easy as you might think.

Biotech is short for biotechnology, a term that references any technology that incorporates biological organisms. Companies that make genetically modified foods fall into this category, as do drugmakers that develop biologic drugs — large, complicated molecules that are manufactured within a living organism.

But while many big pharmaceutical companies develop biologic drugs now, they aren’t usually viewed as biotechs. That’s primarily because these companies make most of their revenue from sources other than biologic drugs.

Also, some drugmakers are typically classified as biotechs even though they don’t make most of their money from biologic drugs. Why? A lot of people call any small drugmaker a “biotech” regardless of whether the drugs it develops use living organisms. Even when these small companies grow to be large, they’re still called biotechs.

If you’re looking to invest in biotech stocks, there is one quick way to determine which stocks are biotechs and which aren’t. You can check out the industry designation for the company on investing sites. On Fool.com, for example, enter the ticker symbol for a given stock and then click on the “Profile” link. If the industry in the company info section is “Med-Biomed/Genetics,” it’s a biotech stock.

2. Determine your risk tolerance

Perhaps the most important step of all with investing in biotech stocks is to determine your risk tolerance. Some investors are aggressive and can tolerate higher levels of risk. Others are more conservative and seek to minimize their risk levels. There’s a big reason you’ll want to know your risk tolerance: It will help you determine which biotech stocks are good investing candidates for you and which aren’t.

If you already know your risk tolerance, great. If you don’t, you might want to complete a risk-tolerance questionnaire to help you determine your investing style.

3. Understand the risks specific to biotech stocks

All stocks have risks. But biotech stocks have some specific risks that aren’t applicable to stocks in many other industries. These risks include clinical failures, regulatory approval setbacks, commercialization problems, and loss of exclusivity/patent expiration.

The risk of clinical failure. Probably the most critical of these biotech-specific risks is the potential of failures in clinical trials. All biotech companies must thoroughly test their experimental drugs to assess the drugs’ safety and efficacy in treating the targeted condition.

This process starts with preclinical testing. Some preclinical testing is conducted in vitro, which literally means “in the glass.” That’s a reference to lab testing in test tubes, culture dishes, and other ways that don’t involve animals or humans. Other preclinical testing is done in vivo, which means “within the living.” This kind of preclinical testing is performed using laboratory animals.

Biotechs that only have experimental drugs in the preclinical stage are especially risky. Most drugs never advance from preclinical testing into clinical studies.

If a drug looks promising in preclinical testing, though, the biotech can seek regulatory approval from the Food and Drug Administration (FDA) in the U.S. or the European Medicines Agency in Europe to begin a phase 1 clinical study. The primary purposes of phase 1 clinical studies are to evaluate the safety of an experimental drug, including identifying possible side effects, and to determine the ideal dosage range for the drug.

Around 37% of drugs that are evaluated in phase 1 clinical studies fail, according to the Biotechnology Innovation Organization (BIO). The successful drugs advance to phase 2 clinical studies. These studies test the efficacy and appropriate dosage levels of the drugs.

Most drugs — nearly 70%, based on BIO’s analysis of historical data — aren’t successful in phase 2 clinical testing. The ones that are move to phase 3 clinical studies, large clinical trials needed to assemble sufficient statistical data that the drugs are both safe and effective. Almost 42% of drugs fail in phase 3 testing.

Overall, only 11% of experimental drugs that begin clinical studies jump all the hurdles needed to file for regulatory approval.

Regulatory approval setbacks. Biotechs still face the risk that drugs that have been successful in clinical studies won’t win regulatory approval. Nearly 15% of drugs submitted for approval get a thumbs-down from the FDA, according to BIO.

In some cases, the biotech can conduct additional clinical studies to persuade regulatory agencies to approve an experimental drug. However, frequently a regulatory rejection means the end of the road for a drug.

Commercialization problems. You might think that once its drug wins regulatory approval, a biotech has it made. Not necessarily. Companies must persuade insurers and government healthcare programs to pay for a new drug.

In the U.S., this process involves working with all of the major insurers and pharmacy benefit managers, as well as Medicare and Medicaid, to provide coverage for a new drug. In Europe, biotechs must negotiate with each country individually for a new drug to be covered.

Invest in Illusio The worlds first Augmented Reality Platform For Cosmetic Surgery

On top of these negotiations, biotechs must build sales teams to promote new drugs to prescribers. In many cases, companies also market directly to consumers via online, print, and TV advertising. Despite all of these efforts, there are significant risks that a biotech will be unsuccessful in achieving commercial success for a new product.

Loss of exclusivity/patent expiration. While biotechs often compete against other drugmakers, they enjoy protection for a while from potential rivals seeking to market generic or biosimilar versions of their drugs. Biologic drugs receive a 12-year period of exclusivity from biosimilar competition, while non-biologic drugs typically have a five-year exclusivity period.

In addition to the exclusivity periods, biotechs usually secure patents on their drugs. These patents expire 20 years after the filing date.

Once a biotech’s drug loses exclusivity and patent protection, rival companies can legally launch “copycat” versions of the drug. This nearly always causes a sharp decline in sales for the biotech’s drug.

4. Know what to look for in a biotech stock

The perfect biotech stock to buy would be one that has a broad lineup of approved drugs on the market. Each of these drugs would generate billions of dollars in annual sales. They would have a long way to go before the loss of exclusivity or patent expiration. And they would enjoy virtual monopolies for the conditions they treat.

This perfect biotech stock would also have a deep pipeline with a lot of candidates in phase 3 testing. The company would be super-profitable with fast-growing revenue and a mountain of cash built up to use in rewarding investors through share buybacks and dividends. And the stock would be dirt cheap.

Unfortunately, such a biotech stock doesn’t exist. However, these ideal qualities of a perfect biotech stock represent the things you should look for, and they fall into four main categories: current product lineup, pipeline, financial position, and valuation. The closer a given biotech stock rates on each measure, the better investment choice it should be.

Many small biotechs won’t have any approved drugs yet. For the biotechs that do, companies with multiple drugs with strong and growing sales will be less risky than others. It’s also a good sign when a biotech has best-selling drugs in multiple therapeutic areas. Diversified revenue sources are nice to have with any stock.

Pipelines can be difficult to evaluate. However, a pipeline that has several drugs in late-stage testing is preferred because they have less risk than experimental drugs in earlier-stage development. You can also check out what analysts and other industry observers have to say about early stage clinical results to get a sense of whether there are any yellow flags with what might otherwise seem to be positive results.

Established biotechs will have stronger financial positions than small clinical-stage biotechs. Strong revenue and earnings growth is a big plus. Regardless of the size of the biotech, though, look at the company’s cash position. A small biotech with no approved products could have to issue new shares if it doesn’t have enough cash, which causes dilution in the value of existing shares. (Think of a pizza with eight slices that’s cut into 16 slices. Anyone who had a slice initially has less pizza to eat after the second slicing.)

With larger biotech stocks, you can use traditional metrics such as price-to-earnings and price-to-earnings-to-growth (PEG) ratios to assess valuations. The key here is to compare these valuation metrics for a given biotech stock against its peers to determine whether it’s relatively cheap or relatively expensive.

The valuations of smaller biotech stocks with no approved drugs are tied to what investors think about the biotechs’ pipeline prospects. It’s difficult to know how reasonable the growth prospects are for pipeline candidates that haven’t been approved yet.

One important thing you can look at with small biotechs, though, is any partnerships that they have established with larger drugmakers. A major drugmaker wouldn’t partner with a smaller biotech without performing due diligence on its pipeline candidates. Having a big partner doesn’t mean that a small biotech’s pipeline isn’t risky, but investors can usually have more confidence in a small biotech’s pipeline candidate when a major drugmaker has put significant money on the line betting on the success of the experimental drug.

5. Evaluate the top biotech stocks and ETFs

The 10 biggest biotech stocks claim market caps (the total market value of a company’s outstanding shares) of at least $30 billion, with several having market caps of more than $100 million. These are the exceptions, though. There are hundreds of biotech stocks with much smaller market caps. In addition, several biotech ETFs are available that hold positions in many individual biotech stocks. Your risk tolerance will dictate which of these biotech investment alternatives are the best fits for you.

To give you a sense of how to evaluate biotech stocks and ETFs, we’ll look at a few examples that might appeal to investors with different risk tolerances. Note that there are no options provided for investors with low-risk tolerances. Why? Biotech stocks and ETFs probably wouldn’t be well suited for these investors.

Alexion Pharmaceuticals. Alexion currently has four approved products, all of which target rare diseases. The biotech’s biggest blockbuster, Soliris, recently won FDA approval for treating another condition, neuromyelitis optica spectrum disorder. Sales are climbing for all four of Alexion’s drugs, with tremendous growth for its newest product, Ultomiris, which market researcher EvaluatePharma thinks will be the biggest new drug launch of 2019.

The biotech’s pipeline includes three late-stage programs targeting rare diseases. In addition, Alexion has four early stage clinical programs.

Alexion appears to be in a strong financial position. Its revenue and earnings continue to grow rapidly. The company also has a substantial cash stockpile that it can use to reward shareholders through stock buybacks or to make strategic business development deals to fuel growth.

While many biotech stocks have sky-high valuations, Alexion is one of the most attractively valued biotechs on the market. Its forward price-to-earnings multiple, which uses estimated earnings rather than historical earnings, and PEG ratio are both low compared with most other biotech stocks.

Alexion faces some risks, including key patents for Soliris beginning to expire in 2021 and the possibility that its clinical programs won’t be successful.

Amgen. Amgen currently claims 18 approved products. Seven of these generated sales of more than $1 billion in 2018. At least two more of the biotech’s approved drugs, Kyprolis and Aimovig, appear to be on the way to becoming blockbusters.

The company’s pipeline includes six late-stage programs, including the pursuit of additional approved indications for three already-approved drugs, plus three biosimilars in development. Amgen also has 26 programs in phase 1 and phase 2 testing.

Amgen generates tremendous cash flow and has one of the largest cash stockpiles in the industry. The company also pays a dividend with an attractive yield. This strong financial position is a key reason investors with moderate risk tolerances might like Amgen.

The biotech’s forward P/E ratio is low. However, some investors might be leery of Amgen’s high PEG ratio.

However, several of Amgen’s top drugs face intense competition. This situation is likely to weigh on Amgen’s growth in the coming years. Amgen’s pipeline is also risky, with 23 programs in phase 1 clinical studies.

Editas Medicine. Editas Medicine is by far the riskiest of the biotech stocks on our list. The company has no approved products and is a long way from even the possibility of launching a drug commercially.

The attraction for Editas is its pipeline. The biotech plans to begin the first in vivo testing of a CRISPR gene editing therapy in humans in 2019. This phase 1 study will evaluate Editas’ lead candidate, EDIT-101, in treating Leber congenital amaurosis type 10, the leading genetic cause of blindness. Allergan is partnering with Editas on developing EDIT-101. Other than EDIT-101, though, Editas’ pipeline consists only of preclinical programs.

Editas has to rely largely on collaboration revenue from Allergan and its other big partner, Celgene, to fund operations. The biotech could have to raise additional cash through issuing new stock in the future.

For a company with no product revenue, Editas’ market cap is quite high. However, the market cap reflects the tremendous excitement among investors about the potential for the biotech’s gene-editing candidates.

But although CRISPR gene editing could be a game-changer in treating diseases, it remains a technology in its infancy. Editas faces considerable challenges in advancing its pipeline candidates.

Vertex Pharmaceuticals. Vertex Pharmaceuticals has three approved drugs on the market, all of which treat the underlying cause of cystic fibrosis (CF). The biotech essentially enjoys a monopoly in CF right now.

It’s likely that Vertex’s pipeline will fuel more growth. The biotech hopes to win approval for a triple-drug CF combo in 2020. This regimen would dramatically increase Vertex’s target patient population. In addition, the biotech’s pipeline includes an experimental pain drug that’s in phase 2 testing and a couple of early stage programs targeting rare diseases.

Vertex’s financial position continues to look better and better as its revenue and profitability increase. The company has a significant amount of cash built up that it plans to use in adding more programs to its pipeline.

While Amgen has a low forward P/E multiple and a high PEG ratio, it’s the opposite case for Vertex. The biotech’s attractive PEG ratio is a sign of the tremendous growth expected for Vertex, with the anticipated launch next year of its triple-drug combo for treating CF.

There is a risk, though, that Vertex could run into regulatory approval problems. The biotech’s pipeline candidates also face risks of failure in clinical studies.

SPDR S&P Biotech ETF. You might wonder why the SPDR S&P Biotech ETF isn’t more suitable for investors with low risk tolerances. Although the ETF holds positions in over 100 biotech stocks, many of these stocks have high or very high risk levels.

For moderately aggressive investors, though, this ETF could be a smart way to profit from growth in the biotech industry. While some of the biotechs among the fund’s holdings could experience pipeline setbacks or other issues, not all of them will.

The primary downside to buying the SPDR S&P Biotech ETF, other than risk, is that the fund has an annual expense ratio of 0.35%. However, that’s not unreasonable, considering the broad basket of biotech stocks the ETF provides.

6. Invest cautiously

Whichever biotech stock or ETF you buy, invest cautiously. Don’t put too much of your portfolio in biotech stocks, because of the risk and volatility associated with the industry.

If you’re buying the stock of a small clinical-stage biotech, you’ll want to be even more cautious. You might consider investing a small amount initially. If clinical study results increase your confidence in the biotech’s prospects, you could then increase your position in the stock.

7. Monitor changing dynamics

The last step for investing in biotech stocks is to monitor changing dynamics. Bad news doesn’t necessarily mean you should sell your biotech stocks, but it could prompt you to do so. Horrible results from a clinical study, for instance, could completely change your entire investing thesis — especially for a clinical-stage biotech.

Keep your eyes on the competition, too. The emergence of new drugs could threaten even a big biotech’s sales.

There’s also the possibility that the reimbursement environment changes dramatically. For example, major changes to the U.S. healthcare system that limit the ability of biotechs to set drug prices would probably negatively affect stock prices.

Back to those adjectives

Yes, investing in biotech stocks can be scary and risky. However, following these seven steps should increase the odds that your experience in investing in biotech stocks is both exciting and lucrative over the long run.

Now that you’ve got the basics,

The post How to Invest in Biotech Stocks appeared first on Investor News.

The tsunami has all but ended in a defeat for many investors and companies. There is finally good news. The JOBS Act 3.0

The jobs act 1.0 and 2.0 delivered a disruption to investing and helped propel small businesses into multimillion dollar companies.  The great rush of Reg. A and Reg. D and  Equity Crowdfunding seems to have all but halted in the last 2 years for many reasons.

Companies were required to only allow investment form verified  Accredited Investors.  The SEC States An accredited investor is a person that the SEC deems is sophisticated enough to protect themselves in making investment decisions and therefore does not require certain additional protections under certain securities laws.  Currently, to be an accredited investor as an individual, you must (1) earn $200,000 (or $300,000 jointly with your spouse) in income over the last 2 years or (2) $1 million in net worth (excluding home value. There was a major downfall in this strategy, many eligible  Accredited Investors, especially in the US had not verified their status nor had they been given the right material to understand the investments criteria.

Start Up Companies were busy building and marketing their pitch decks and dealing with all the relevant road shows and right things to say. The companies themselves failed to deliver on then best strategy of all to entice investors, and exit strategy.

Indiegogo, Crowdfunder and Start Engine were co-conspirators in a race to entice companies to list on their platforms they did not divulge to the companies that the main strategy investors seek is exits to IPO, Mergers and  Buy Outs.

As with the ICO craze of 2016, many companies made money in marketing and investor relations and many investors did eventually invest only to be dismayed at the lack of forethought in these projects. Over 90% of the ICOs from 2016 are now gone with millions being lost across the board.

While, the JOBS Act gave investors a new avenue and helped companies to deliver an alternative investing vehicle, the accredited investors, were this time left holding the bag.  As more companies were being listed the pool of investors got smaller and less tolerant of mistakes.

In 2014 – 2016 every start up company was the “Uber of ” or was “disrupting some form of economy”, the vast majority of those companies too have run out of funds, or never reached market with their product, even after there was a sizable investment from the members of the equity crowdfunding platforms.

WHAT DOES JOBS ACT 3.0 MEAN FOR COMPANIES?

The JOBS Act 3.0 should be the game changer. This should finally open the doors to investment like never before allowing investors to be accredited by their experience rather than their wealth.

It is now on the companies themselves to deliver solid growth plans and solid ideas. They should have a good team on board who are more than just friends from school and college.  The companies need guidance by seasoned personnel, rather than giving titles out to anyone in the room based on their needs.

The lack of quality education on Equity Crowdfunding and investing is still astonishing in today’s digital age where many  16 year olds had Youtube channels devoted to Crypto.

WHAT IS IN THE FUTURE FOR JOBS ACT 3.0 AND INVESTORS

The JOBS Act 3.0 gives many updates and addendums to the previous 2 JOBS Acts.

The Launch of Venture Exchange is one of the more ambitious and lofty elements, this will no doubt lead to a rush venture exchanges  being brought to market.  It stands to reason, that companies with 10,000 shares should not be regulated equally to those with 10 million shares. The Act 3.0 would allow for the registration of “venture exchanges” with the SEC to provide a venue for small and emerging companies and offer a platform to trade their securities. It would also permit the trading of venture securities, which would apply to early stage companies whose shares are Regulation A+ securities, as well as listed companies whose shares are below the average daily trade volume. The creation of venture exchanges would help even the playing field such that small and startup companies could attract investors.

HOW WILL THIS JOBS ACT 3.0 IMPACT MARIJUANA COMPANIES?

Marijauana and Cannabis companies should be able to utilize some of the many relaxed rules including  the rules for filing confidential IPOs. The current rules permit “an emerging growth company” or any person authorized to act on its behalf file confidentially. The Act 3.0 proposes to change the wording to “an issuer” or any person authorized to act on its behalf. This would widen the pool of companies able to explore confidential filings.

JOBS ACT 3.0 EASING OF REGULATORY BURDENS

The fourth objective of JOBS Act 3.0 is to reduce the economic costs of going public by relaxing the requirements for companies to produce quarterly financial reports. On average, initial regulatory compliance costs more than $1 million in one-time costs associated with an IPO. The Act 3.0 directs the SEC to analyze the costs and benefits of quarterly reports and provide recommendations to Congress for decreasing costs, increasing transparency, and increasing efficiency of quarterly financial reporting. The aim is to allow smaller companies to delay various financial reporting requirements. These tactics would enable more companies to secure an IPO by allowing them to spread the cost over a longer period of time, thus reducing the financial burden of going public.

The Marijuana Industry should be rejoicing and hoping to capitalize on these relaxed regulations along with the recent victory and landmark legalization of marijuana in Illinois just last week. Marijuana, Cannabis and CBD companies now have better access to a larger pool of investors , with less regulation at a critical time for the Cannabis markets.

Accredited Investors can now come for a new class in the investor pool and be self directed. This will help deliver a huge influx of investors into the market and so long as companies have a clear path to exit and solid team this is a win for all.

MARIJUANA INVESTORS SHOULD NOW START LINING UP THEIR PORTFOLIOS FOR 2019-2021

The new acceptance of investment in Cannabis and Marijuana markets as legitimate, of not federally legal yet, is a huge boost for famers, growers and research scientists interested in releasing new medical treatments for Cancer, Addiction, Mood disorders and pain relief.

As more states legalize both in medical marijuana and recreational marijuana use, the older propaganda is not able to out do the merits and positive reports especially from the medical marijuana and CBD research camps.

The older “Reefer Madness” days are slowly fading away as more scientific research points to the legitimate use of these plants and their extracts beyond rolling joints.

The post How The JOBS Act 3.0 should boost Marijuana Investment appeared first on Investor News.

The post Marijuana will be Legal in Illinois appeared first on Investor News.